Premium
Exploring Innovative Leishmaniasis Treatment: Drug Targets from Pre‐Clinical to Clinical Findings
Author(s) -
Santana Wanessa,
Oliveira Simone S. C.,
Ramos Mariana H.,
Santos André L. S.,
Dolabella Silvio S.,
Souto Eliana B.,
Severino Patrícia,
Jain Sona
Publication year - 2021
Publication title -
chemistry and biodiversity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.427
H-Index - 70
eISSN - 1612-1880
pISSN - 1612-1872
DOI - 10.1002/cbdv.202100336
Subject(s) - leishmaniasis , leishmania , drug , protozoa , mucocutaneous zone , repurposing , cutaneous leishmaniasis , visceral leishmaniasis , pharmacology , drug repositioning , clinical trial , medicine , disease , immunology , dermatology , biology , microbiology and biotechnology , parasite hosting , ecology , world wide web , computer science
Leishmaniasis is a group of tropical diseases caused by parasitic protozoa belonging to the genus Leishmania . The disease is categorized in cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL). The conventional treatment is complex and can present high toxicity and therapeutic failures. Thus, there is a continuing need to develop new treatments. In this review, we focus on the novel molecules described in the literature with potential leishmanicidal activity, categorizing them in pre‐clinical ( in vitro , in vivo) , drug repurposing and clinical research.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom